Video

Dr John C. Morris Highlights Exciting Developments in Lung Cancer Immunotherapy

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.

Ongoing studies are using these inhibitors in combination with each other and with cancer vaccines. Early results of one of his own clinical trials of the HyperAcute lung vaccine has shown the vaccine to be safe and that very heavily pre-treated patients may benefit from it,

"The results will be very interesting if it shakes out that the vaccine has results that are either equal to or better than the standard of care," Dr Morris said. He added, "Chemotherapy has the typical chemotherapy side effects; the vaccine has had none of these side effects."

Related Videos
Shawn Griffin, MD, sitting for a video interview
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Dr K. Vish Viswanath
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
Dr Kimlin Tam Ashing
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo